Veracyte, Inc. (VCYT)
VCYT moved a median of -0.15% 30 minutes after news, and -0.05% by the close. How VCYT actually reacts to news — the realized, point-in-time move the market made, measured across 427 labeled events over the last three years with zero look-ahead.
VCYT’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.08% | 53% | 426 |
| 30-min | -0.15% | 46% | 426 |
| 60-min | 0.00% | 49% | 426 |
| to close | -0.05% | 49% | 424 |
| Middle 50% of VCYT reactions | -1.25% to +1.34% |
|---|---|
| Median reaction (30-min) | -0.15% |
| Measured reactions | 427 |
Half of all Veracyte, Inc. news events land between -1.25% and +1.34% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How VCYT reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 16 | +0.68% | 69% | +0.67% |
| Analyst downgrades | 13 | -0.02% | 46% | +0.82% |
| Coverage initiations | 22 | +0.14% | 64% | +0.80% |
| Rating reiterations | 80 | +0.07% | 56% | -0.12% |
| Price-target raises | 16 | -0.32% | 31% | -1.23% |
| Price-target cuts | 13 | -0.27% | 39% | +0.96% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. See how VCYT ranks against every other measured name →
That’s how VCYT usually reacts — get an email when it moves on news →Email me when VCYT moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to VCYT's baseline. Nothing else.
Recent VCYT events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Phase III Trial Demonstrates Veracyte’s Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation | Press release | GlobeNewswire | +1.48% | +0.17% | |
| Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026 | Press release | GlobeNewswire | +1.52% | +0.42% | |
| Form 8-K VERACYTE, INC. For: Sep 10 | SEC filing · Form 8-K | SEC EDGAR | +0.48% | +2.03% | |
| Form 8-K VERACYTE, INC. For: Sep 10 | SEC filing · Form 8-K | SEC EDGAR | +1.84% | -1.69% | |
| Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform | Press release | GlobeNewswire | +1.84% | -1.69% | |
| Veracyte to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference | Press release | GlobeNewswire | +2.18% | +3.15% | |
| Form 10-Q VERACYTE, INC. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.46% | -3.26% | |
| Form 8-K VERACYTE, INC. For: Jul 30 | SEC filing · Form 8-K | SEC EDGAR | -4.00% | -5.37% | |
| Veracyte Announces Second Quarter 2026 Financial Results | Press release | GlobeNewswire | -4.00% | -5.37% | |
| Veracyte to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.52% | -0.57% | |
| Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026 | Press release | Business Wire | -1.29% | -3.60% | |
| Form 8-K VERACYTE, INC. For: Jun 10 | SEC filing · Form 8-K | SEC EDGAR | -0.60% | -0.38% | |
| Form S-8 VERACYTE, INC. | SEC filing · Form S-8 | SEC EDGAR | -1.34% | -2.49% | |
| Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S. | Press release | Business Wire | -1.58% | +4.33% | |
| ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer | Press release | Business Wire | -1.58% | +4.33% | |
| Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy | Press release | Business Wire | +0.15% | -1.15% | |
| Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings | Press release | Business Wire | -0.66% | -0.95% | |
| OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer | Press release | Business Wire | -0.66% | -0.95% | |
| Veracyte to Participate in Upcoming Investor Conferences | Press release | Business Wire | +0.70% | +7.19% | |
| Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer | Press release | Business Wire | +0.75% | +0.81% | |
| Form 10-Q VERACYTE, INC. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -2.35% | +8.25% | |
| Form 8-K VERACYTE, INC. For: May 05 | SEC filing · Form 8-K | SEC EDGAR | -2.35% | +8.25% | |
| Veracyte Announces First Quarter 2026 Financial Results | Press release | Business Wire | -2.35% | +8.25% | |
| Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers | Press release | Business Wire | -0.69% | -1.15% | |
| Form ARS VERACYTE, INC. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -1.29% | -1.78% | |
| Form DEF 14A VERACYTE, INC. For: Jun 10 | SEC filing · Form DEF | SEC EDGAR | -1.29% | -1.78% | |
| Form DEFA14A VERACYTE, INC. | SEC filing · Form DEFA14A | SEC EDGAR | -1.29% | -1.78% | |
| Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026 | Press release | Business Wire | +0.57% | -0.76% | |
| Form 8-K VERACYTE, INC. For: Mar 13 | SEC filing · Form 8-K | SEC EDGAR | +1.30% | +1.39% | |
| Veracyte Names Kevin Haas as Chief Development and Technology Officer | Press release | Business Wire | +1.30% | +1.39% | |
| Form 10-K VERACYTE, INC. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +1.26% | -3.53% | |
| Form 8-K VERACYTE, INC. For: Feb 25 | SEC filing · Form 8-K | SEC EDGAR | +3.12% | +0.62% | |
| Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results | Press release | Business Wire | +3.12% | +0.62% | |
| Veracyte to Highlight Extensive Decipher® Data at 2026 ASCO GU Symposium | Press release | Business Wire | -0.38% | -0.06% | |
| Veracyte to Participate in Upcoming Investor Conferences | Press release | Business Wire | -0.97% | -1.38% | |
| Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026 | Press release | Business Wire | +1.72% | -3.52% | |
| Form 8-K VERACYTE, INC. For: Jan 11 | SEC filing · Form 8-K | SEC EDGAR | +1.47% | +2.36% | |
| Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results | Press release | Business Wire | +1.47% | +2.36% | |
| Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference | Press release | Business Wire | -0.86% | -1.45% | |
| Veracyte to Participate in Upcoming Investor Conferences | Press release | Business Wire | -0.64% | -7.72% | |
| Form 10-Q VERACYTE, INC. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +7.69% | +15.10% | |
| Form 8-K VERACYTE, INC. For: Nov 04 | SEC filing · Form 8-K | SEC EDGAR | +7.69% | +15.10% | |
| Veracyte Announces Third Quarter 2025 Financial Results | Press release | Business Wire | +7.69% | +15.10% | |
| Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing | Press release | Business Wire | -0.95% | +1.26% | |
| Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025 | Press release | Business Wire | +0.65% | +1.56% | |
| Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer | Press release | Business Wire | -1.11% | +0.54% | |
| Veracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Will Be Presented at ASTRO 2025 | Press release | Business Wire | +0.59% | -3.57% | |
| Veracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual Meeting | Press release | Business Wire | +0.53% | -0.90% | |
| Veracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference | Press release | Business Wire | +0.38% | +0.90% | |
| Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer | Press release | Business Wire | +0.58% | +0.60% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the VCYT section they belong to.
Where else VCYT is measured.
VCYT earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| TRULIEVE CANNABIS CORP (TCNNF) | 429 | +0.41% | 58% |
| Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares (KNSA) | 427 | -0.21% | 39% |
| Moleculin Biotech, Inc. (MBRX) | 426 | -0.21% | 43% |
| Summit Therapeutics Inc. (SMMT) | 426 | +0.03% | 50% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Veracyte, Inc.'s median reaction calculated?
Every labeled VCYT news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 427 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 46% of VCYT's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does VCYT's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.